Drug · CHEMBL1016
CANDESARTAN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CANDESARTAN. Drugs and targets, record CHEMBL1016. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1016
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Blopress, CV-11974, Candemore, Candesartan cilexetil related compound g, NSC-759858
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | Type-1 angiotensin II receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/185 |
Source ChEMBL
Diseases45
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 45Source Open Targets
See all 45 diseasesTrials107
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 30 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00252733 | Diabetic Retinopathy Candesartan Trials | Phase 3 | 5,238 | 2012-04-13 | candesartan | Its name | ClinicalTrials.gov |
| NCT00252694 | DIabetic Retinopathy Candesartan Trials | Phase 3 | 4,717 | 2014-06-06 | candesartan | Its name | ClinicalTrials.gov |
| NCT00252720 | DIabetic Retinopathy Candesartan Trials. | Phase 3 | 1,850 | 2014-06-03 | candesartan | Its name | ClinicalTrials.gov |
| NCT00081731 | Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions | Phase 3 | 947 | 2014-01-29 | candesartan | Its name | ClinicalTrials.gov |
| NCT00348686 | Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP) | Phase 4 | 315 | 2012-04-02 | candesartan | Its name | ClinicalTrials.gov |
| NCT00391846 | Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone | Phase 4 | 252 | 2012-06-18 | candesartan | Its name | ClinicalTrials.gov |
| NCT01984164 | CAndesartan vs LIsinopril Effects on the BRain | Phase 2 | 176 | 2021-02-21 | candesartan | Its name | ClinicalTrials.gov |
| NCT00607672 | The RAS, Fibrinolysis and Cardiopulmonary Bypass | Phase 4 | 111 | 2012-10-10 | candesartan | Its name | ClinicalTrials.gov |
| NCT02646982 | Candesartan's Effects on Alzheimer's Disease And Related Biomarkers | Phase 2 | 77 | 2022-09-29 | candesartan | Its name | ClinicalTrials.gov |
| NCT03640312 | Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension | Phase 2 | 62 | 2023-09-22 | candesartan | Its name | ClinicalTrials.gov |
1 to 10 of 107
See all 107 trialsComparisons in its trials46
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Candesartan vs Placebo: Number of Participants With at Least a 3 Step Improvement or a Persistent 2-step Improvement in the ETDRS Severity Scale. | 180 of 951 | 136 of 954 | 1,905 | NCT00252694 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale | 161 of 951 | 182 of 954 | 1,905 | NCT00252694 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR). | 192 of 951 | 193 of 954 | 1,905 | NCT00252694 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale | 127 of 951 | 124 of 954 | 1,905 | NCT00252720 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR). | 110 of 951 | 107 of 954 | 1,905 | NCT00252720 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With a Regression of Diabetic Retinopathy. | 140 of 951 | 139 of 954 | 1,905 | NCT00252720 | Trial comparisons |
| Candesartan vs Placebo: serious adverse events | 301 of 949 | 267 of 953 | 1,902 | NCT00252694 | Trial comparisons |
| Candesartan vs Placebo: serious adverse events | 173 of 951 | 161 of 951 | 1,902 | NCT00252720 | Trial comparisons |
| Candesartan vs Placebo: Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale. | 178 of 711 | 217 of 710 | 1,421 | NCT00252733 | Trial comparisons |
| Candesartan vs Placebo: serious adverse events | 102 of 710 | 112 of 710 | 1,420 | NCT00252733 | Trial comparisons |
1 to 10 of 46
See all 46 comparisons in its trialsPapers from its trials106
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials10
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Trail Making Test B | 3 | 2 | ConductCognition |
| Verbal Learning | 3 | 1 | ConductCognition |
| Category Fluency | 2 | 1 | ConductCognition |
| Digit Span Test | 2 | 1 | ConductCognition |
| Eriksen Flanker Task | 2 | 1 | ConductCognition |
| 1-Back Task | 2 | 1 | ConductCognition |
| Verbal Fluency | 2 | 1 | ConductCognition |
| Complex Figure Copy and Recall | 1 | 0 | ConductCognition |
| Picture Naming Test | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1016
GET https://conductscience.org/api/drugs/v1/CHEMBL1016/diseases?page=2